This inventor holds 1 USPTO granted patent. Top assignee: Apotex Pharmachem Inc.. Active years: 2011.
Company Filing History:
Years Active: 2011
Title: The Innovations of Matthew A. Buck
Introduction
Matthew A. Buck is an accomplished inventor based in Waterloo, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of new drug formulations. His work has led to advancements that can potentially improve patient outcomes.
Latest Patents
Matthew A. Buck holds a patent for an innovative amorphous form of ziprasidone hydrochloride. This compound, known scientifically as 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride, is notable for its unique properties and processes for production. The patent highlights the potential benefits of this new formulation in therapeutic applications.
Career Highlights
Matthew A. Buck is currently associated with Apotex Pharmachem Inc., a leading company in the pharmaceutical industry. His role involves research and development, focusing on innovative drug formulations that can enhance the efficacy and safety of medications. His expertise in this area has been instrumental in driving forward the company's research initiatives.
Collaborations
Throughout his career, Matthew has collaborated with several talented individuals, including Carlos Zetina-Rocha and Allan W. Rey. These collaborations have fostered a creative environment that encourages the exchange of ideas and the development of groundbreaking solutions in the pharmaceutical field.
Conclusion
Matthew A. Buck's contributions to the pharmaceutical industry exemplify the impact of innovation in healthcare. His work on the amorphous form of ziprasidone hydrochloride showcases his commitment to improving drug formulations. Through his career and collaborations, he continues to make strides in advancing medical science.